SAN FRANCISCO--(Business Wire)--
Aberdare Ventures, a healthcare technology venture capital firm,
today announced that Y. Vincent Kim and Naheed Ismaili Misfeldt,
formerly principals, have been promoted to partners of the firm. They
join Managing Partner Paul Klingenstein, and Partners Sami Hamade, Dan
Kisner, and Jake Odden.
Mr. Kim, 34, joined Aberdare in 2002 and specializes in
therapeutic medical device companies. He currently serves as a
director of Ample Medical. He is responsible for the firm's
investments in Ablation Frontiers and VertiFlex, and led the
evaluations of EnteroMedics and Posit Science. Prior to joining
Aberdare, he was an Associate at Acacia Venture Partners, where he
participated in venture capital investments in healthcare services and
information technology companies. Previously, Mr. Kim worked at APM, a
healthcare-focused strategy and operations consulting firm.
Ms. Misfeldt, 34, a principal at Aberdare since 2003, specializes
in biopharmaceutical product companies. She is currently a director of
Visionary Therapeutics. She has played a central role in many Aberdare
investments, including Conatus Pharmaceuticals, BioVerdant, Avera
Pharmaceuticals, Mpex Pharmaceuticals and Ruxton Pharmaceuticals. Ms.
Misfeldt joined Aberdare from Bay City Capital, and earlier, she was
an Associate in the Healthcare Group at Chase H&Q.
About Aberdare Ventures
Aberdare Ventures is a San Francisco-based venture capital firm
focused on healthcare technology investments. Aberdare manages three
successive funds, and was founded in 1999. For more information,
please visit www.aberdare.com.
Aberdare Ventures
Jake Odden or Paul Klingenstein, 415-392-7442
Copyright Business Wire 2008
